Delivery Order SPE2DB22D3501-SPE2DB25FXG09
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract ceiling value of $1,773.46. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $1,231.76. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and no set-aside designation was applied. The award represents a competitive procurement executed under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,680.85 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on September 8, 2025, with an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency awarded a $2,735.43 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a child order under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,253.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $2,323.60 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed price delivery order represents a small-value pharmaceutical procurement with no set-aside designation. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,372.32 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work is to...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXG09Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,018.10 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery transaction under AmerisourceBergen's existing contract vehicle with DLA. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor for the Defense Logistics Agency, AmerisourceBergen supplies a comprehensive portfolio of medications and medical commodities to support military and veteran healthcare systems globally. The Vyvanse supply fulfills federal medical procurement needs for stimulant medication used in attention deficit disorder treatment, consistent with the contractor's extensive portfolio of brand-name and generic pharmaceuticals delivered across multiple therapeutic domains to Department of Defense healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/10/25 |